Market Cap 11.48B
Revenue (ttm) 3.80B
Net Income (ttm) 484.21M
EPS (ttm) N/A
PE Ratio 22.30
Forward PE 25.78
Profit Margin 12.76%
Debt to Equity Ratio 0.20
Volume 2,159,800
Avg Vol 2,650,206
Day's Range N/A - N/A
Shares Out 834.65M
Stochastic %K 43%
Beta 0.27
Analysts Hold
Price Target $15.50

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equival...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
briefingcom
briefingcom May. 18 at 12:36 PM
$RDY: Dr. Reddy's launches its generic semaglutide injection in Canada https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260518061903RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
AlertsAndNews
AlertsAndNews May. 16 at 7:46 PM
$RDY $NVO Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada "The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada"
1 · Reply
MarketBeat
MarketBeat May. 14 at 12:11 PM
https://marketbeat.com/a/8654460/ $RDY Dr. Reddy's Laboratories Q4 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:21 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
0 · Reply
ontariomark
ontariomark May. 12 at 6:53 PM
$RDY News: Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY)
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 2:20 PM
$RDY Share Price: $12.34 Contract Selected: Dec 18, 2026 $12.5 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.58 – $5.60 Potential Upside: 62% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 10:54 AM
$RDY Price: $13.14 (-0.68%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.88% RSI: 56.8 | Momentum: Moderate Volume: +21.1% vs avg Volatility: 1.96% Support: $12.77 | Resistance: $14.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
MStocktwit
MStocktwit Apr. 30 at 5:20 PM
$NVO $RDY $LLY Exact copy from the Novo with different branded label. Better than a Generic. Approved last year. Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
Gnomsayin
Gnomsayin Apr. 29 at 7:48 PM
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 6:02 PM
$NVO $RDY $LLY Novo changes the label and you have the generic ready to go. Source http://www.endorhealth.com/article/generic-ozempic-coming-to-canada#:~:text=Eli%20Lilly%20has%20stated%20it,rebranded%20versions%20on%20December%2022%3A
0 · Reply
Latest News on RDY
Dr Reddy’s rolls out oral semaglutide in India

2026-05-20T16:22:22.000Z - 7 days ago

Dr Reddy’s rolls out oral semaglutide in India


Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Thu, 14 May 2026 08:12:39 -0400 - 14 days ago

Dr. Reddy's Laboratories Q4 Earnings Call Highlights


Dr Reddy’s Labs Q4 net profit plunges 86%

2026-05-12T18:11:26.000Z - 15 days ago

Dr Reddy’s Labs Q4 net profit plunges 86%


Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss

2026-05-12T17:58:44.000Z - 15 days ago

Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss


Dr. Reddy's Laboratories Transcript: Q4 25/26

May 12, 2026, 10:00 AM EDT - 16 days ago

Dr. Reddy's Laboratories Transcript: Q4 25/26


Dr. Reddy's Laboratories Quarterly report: Q4 2026

May 12, 2026, 10:00 AM EDT - 16 days ago

Dr. Reddy's Laboratories Quarterly report: Q4 2026


Dr. Reddy's Laboratories Slides: Q4 2026

May 12, 2026, 10:00 AM EDT - 16 days ago

Dr. Reddy's Laboratories Slides: Q4 2026


Indian drugmaker Dr Reddy's posts quarterly profit slump

Tue, 12 May 2026 07:16:09 -0400 - 16 days ago

Indian drugmaker Dr Reddy's posts quarterly profit slump


Canada gives nod for Dr Reddy’s semaglutide

2026-04-29T21:55:00.000Z - 4 weeks ago

Canada gives nod for Dr Reddy’s semaglutide


Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

Wed, 29 Apr 2026 12:37:00 -0400 - 4 weeks ago

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic


Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026

2026-04-24T09:09:58.000Z - 4 weeks ago

Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026


Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs

2026-04-23T19:26:30.000Z - 4 weeks ago

Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs


Dr. Reddy's (RDY) Shares Surge on Generic Drug News

2026-04-23T17:28:22.000Z - 4 weeks ago

Dr. Reddy's (RDY) Shares Surge on Generic Drug News


Dr. Reddy’s reports FDA acceptance to review Abatacept BLA

2026-02-20T16:00:22.000Z - 3 months ago

Dr. Reddy’s reports FDA acceptance to review Abatacept BLA


Dr. Reddy's Laboratories Transcript: Q3 25/26

Jan 21, 2026, 9:00 AM EST - 4 months ago

Dr. Reddy's Laboratories Transcript: Q3 25/26


Dr. Reddy's Laboratories Quarterly report: Q3 2026

Jan 21, 2026, 9:00 AM EST - 4 months ago

Dr. Reddy's Laboratories Quarterly report: Q3 2026


Dr. Reddy's Laboratories Slides: Q3 2026

Jan 21, 2026, 9:00 AM EST - 4 months ago

Dr. Reddy's Laboratories Slides: Q3 2026


Dr. Reddy's Laboratories Transcript: Q2 25/26

Oct 24, 2025, 10:00 AM EDT - 7 months ago

Dr. Reddy's Laboratories Transcript: Q2 25/26


Dr. Reddy's Laboratories Quarterly report: Q2 2026

Oct 24, 2025, 10:00 AM EDT - 7 months ago

Dr. Reddy's Laboratories Quarterly report: Q2 2026


Dr. Reddy's Laboratories Slides: Q2 2026

Oct 24, 2025, 10:00 AM EDT - 7 months ago

Dr. Reddy's Laboratories Slides: Q2 2026


Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 11 months ago

Dr. Reddy's Q1FY26 Financial Results


Dr. Reddy's Laboratories Transcript: Q1 25/26

Jul 23, 2025, 10:00 AM EDT - 11 months ago

Dr. Reddy's Laboratories Transcript: Q1 25/26


Dr. Reddy's Laboratories Quarterly report: Q1 2026

Jul 23, 2025, 10:00 AM EDT - 11 months ago

Dr. Reddy's Laboratories Quarterly report: Q1 2026


Dr. Reddy's Laboratories Slides: Q1 2026

Jul 23, 2025, 10:00 AM EDT - 11 months ago

Dr. Reddy's Laboratories Slides: Q1 2026


Dr. Reddy’s upgraded to Buy from Hold at HSBC

2025-06-05T08:50:09.000Z - 1 year ago

Dr. Reddy’s upgraded to Buy from Hold at HSBC


Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results


Dr. Reddy's Laboratories Transcript: Q4 24/25

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Transcript: Q4 24/25


Dr. Reddy's Laboratories Annual report: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Annual report: Q4 2025


Dr. Reddy's Laboratories Slides: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Slides: Q4 2025


Dr. Reddy's Laboratories Annual report: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Annual report: Q4 2025


Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 1 year ago

Dr. Reddy's Q3 & 9MFY25 Financial Results


Dr. Reddy's Laboratories Transcript: Q3 24/25

Jan 23, 2025, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Transcript: Q3 24/25


Dr. Reddy's Laboratories Quarterly report: Q3 2025

Jan 23, 2025, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q3 2025


Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results


Dr. Reddy's Laboratories Transcript: Q2 24/25

Nov 5, 2024, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Transcript: Q2 24/25


Dr. Reddy's Laboratories Quarterly report: Q2 2025

Nov 5, 2024, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q2 2025


Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 1 year ago

Dr. Reddy's Q1FY25 Financial Results


Dr. Reddy's Laboratories Transcript: Q1 24/25

Jul 27, 2024, 7:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Transcript: Q1 24/25


Dr. Reddy's Laboratories Quarterly report: Q1 2025

Jul 27, 2024, 7:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q1 2025


Dr. Reddy's Laboratories Transcript: M&A Announcement

Jun 26, 2024, 9:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Transcript: M&A Announcement


Dr. Reddy's Laboratories Press release: M&A Announcement

Jun 26, 2024, 9:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Press release: M&A Announcement


Dr. Reddy's Laboratories Slides: Investor presentation

Jun 1, 2024, 6:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Slides: Investor presentation


Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 7, 2024, 10:31 AM EDT - 2 years ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results


Dr. Reddy's Laboratories Transcript: Q4 23/24

May 7, 2024, 10:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Transcript: Q4 23/24


Dr. Reddy's Laboratories Quarterly report: Q4 2024

May 7, 2024, 10:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Quarterly report: Q4 2024


Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 31, 2024, 9:44 AM EST - 2 years ago

Dr. Reddy's Q3 & 9M FY24 Financial Results


Dr. Reddy's Laboratories Transcript: Q3 23/24

Jan 30, 2024, 9:00 AM EST - 2 years ago

Dr. Reddy's Laboratories Transcript: Q3 23/24


Dr. Reddy's Laboratories Quarterly report: Q3 2024

Jan 30, 2024, 9:00 AM EST - 2 years ago

Dr. Reddy's Laboratories Quarterly report: Q3 2024


India's Dr. Reddy's R&D centre being inspected by US FDA

Dec 5, 2023, 4:41 AM EST - 2 years ago

India's Dr. Reddy's R&D centre being inspected by US FDA


Dr. Reddy's Q2 FY24 Financial Results

Oct 27, 2023, 1:50 PM EDT - 2 years ago

Dr. Reddy's Q2 FY24 Financial Results


Dr. Reddy's Laboratories Transcript: Q2 23/24

Oct 27, 2023, 10:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Transcript: Q2 23/24


Dr. Reddy's Laboratories Quarterly report: Q2 2024

Oct 27, 2023, 10:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Quarterly report: Q2 2024


Dr. Reddy's Q1 FY24 Financial Results

Jul 26, 2023, 12:31 PM EDT - 3 years ago

Dr. Reddy's Q1 FY24 Financial Results


Dr. Reddy's Laboratories Transcript: Q1 23/24

Jul 26, 2023, 10:00 AM EDT - 3 years ago

Dr. Reddy's Laboratories Transcript: Q1 23/24


Dr. Reddy's Laboratories Quarterly report: Q1 2024

Jul 26, 2023, 10:00 AM EDT - 3 years ago

Dr. Reddy's Laboratories Quarterly report: Q1 2024


Dr. Reddy's Laboratories Slides: Q1 2024

Jul 26, 2023, 10:00 AM EDT - 3 years ago

Dr. Reddy's Laboratories Slides: Q1 2024


Dr. Reddy's Q4 & FY23 Financial Results

May 10, 2023, 11:43 AM EDT - 3 years ago

Dr. Reddy's Q4 & FY23 Financial Results


Dr. Reddy's Laboratories Transcript: Q4 22/23

May 10, 2023, 10:00 AM EDT - 3 years ago

Dr. Reddy's Laboratories Transcript: Q4 22/23


Dr. Reddy's Laboratories Quarterly report: Q4 2023

May 10, 2023, 10:00 AM EDT - 3 years ago

Dr. Reddy's Laboratories Quarterly report: Q4 2023


Dr. Reddy's: A Profitable, Predictable Margin Expander

May 8, 2023, 12:29 PM EDT - 3 years ago

Dr. Reddy's: A Profitable, Predictable Margin Expander


briefingcom
briefingcom May. 18 at 12:36 PM
$RDY: Dr. Reddy's launches its generic semaglutide injection in Canada https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260518061903RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
AlertsAndNews
AlertsAndNews May. 16 at 7:46 PM
$RDY $NVO Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada "The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada"
1 · Reply
MarketBeat
MarketBeat May. 14 at 12:11 PM
https://marketbeat.com/a/8654460/ $RDY Dr. Reddy's Laboratories Q4 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:21 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
0 · Reply
ontariomark
ontariomark May. 12 at 6:53 PM
$RDY News: Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY)
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 2:20 PM
$RDY Share Price: $12.34 Contract Selected: Dec 18, 2026 $12.5 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.58 – $5.60 Potential Upside: 62% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 10:54 AM
$RDY Price: $13.14 (-0.68%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.88% RSI: 56.8 | Momentum: Moderate Volume: +21.1% vs avg Volatility: 1.96% Support: $12.77 | Resistance: $14.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
MStocktwit
MStocktwit Apr. 30 at 5:20 PM
$NVO $RDY $LLY Exact copy from the Novo with different branded label. Better than a Generic. Approved last year. Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
Gnomsayin
Gnomsayin Apr. 29 at 7:48 PM
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 6:02 PM
$NVO $RDY $LLY Novo changes the label and you have the generic ready to go. Source http://www.endorhealth.com/article/generic-ozempic-coming-to-canada#:~:text=Eli%20Lilly%20has%20stated%20it,rebranded%20versions%20on%20December%2022%3A
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 5:48 PM
$NVO $RDY $LLY In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
ForestFoxes
ForestFoxes Apr. 29 at 5:29 PM
$LLY $NVO $RDY Dr. Reddy's Laboratories (RDY) is strongly connected with Coya Therapeutics $COYA through a strategic partnership, licensing agreement, and financial investment 🙂
0 · Reply
Ro_Patel
Ro_Patel Apr. 29 at 5:26 PM
Health Canada approves $RDY generic version of $NVO Ozempic (patent expired in January) Canada is the first in the G7 forum to approve a generic version of the treatment Also, reviewing 8 other submissions for generic GLP-1 treatments & expects to make regulatory decisions in the coming weeks & months Some generic medications in Canada can be 45% to 90% cheaper than their brand name equivalents A monthly supply of Ozempic or Wegovy costs b/n $300-$400 — sometimes even more depending on the dose A recent survey suggested about 3M Canadian adults are currently taking GLP-1 drugs, such as Ozempic or Mounjaro, and that many more would like to, but cost is a barrier. $LLY
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 12:55 PM
$RDY RSI: 34.35, MACD: 0.0416 Vol: 0.18, MA20: 14.40, MA50: 13.96 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 4 at 1:25 PM
$RDY Share Price: $14.24 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $1.21 – $1.49 Target Zone: $2.20 – $2.69 Potential Upside: 72% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Fhebre
Fhebre Feb. 25 at 11:09 PM
0 · Reply
afterhoursearnings
afterhoursearnings Feb. 25 at 5:11 AM
0 · Reply
Jwa68
Jwa68 Feb. 13 at 1:57 PM
$COYA $RDY $AZN $LLY $NVO Great read. Very well composed. Dr Reddy's and David Einhorn both own 9.9% of the company, just under 20% togethor.
0 · Reply
TalkMarkets
TalkMarkets Feb. 13 at 11:47 AM
Coya Therapeutics Stock Poised To Appreciate As Company Advances Superior ALS Therapy $COYA Also $RDY $AZN $LLY $NVO https://talkmarkets.com/content/stocks--equities/coya-therapeutics-stock-poised-to-appreciate-as-company-advances-superior-als-therapy?post=557175&userid=166882
0 · Reply
Shanna788
Shanna788 Feb. 9 at 4:59 PM
$RDY Company stock current PE 18.60 times, at current price US$14.17, target US$49.85, at PE 59.88 times. The fair USA market PE is 59.88 times [100/(cash deposit return %4.27 minus current inflation rate %2.60)] Other stock positive indicators Operating CF - Positive, shares outstanding (Diluted) - Steady, Revenue, Net profit - Trend up.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 6 at 1:24 AM
$RDY Share Price: $13.97 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $0.69 – $0.85 Target Zone: $1.27 – $1.55 Potential Upside: 74% ROI Time to Expiration: 224 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply